Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
暂无分享,去创建一个
A. Órfão | J. S. San Miguel | N. de Las Heras | M. Vidriales | R. García-Sanz | M. Mateos | J. Alonso | A. Bárez | J. Hernández | J. Galende | Alejandro Martín | E. Pérez‐Persona | G. Mateo | A. G. de Coca | G. Martín-Núñez | C. López-Berges | J. Hernández | G. Martín‐Nuñez | N. de las Heras | Alfonso García de Coca
[1] A. Órfão,et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.
[2] Marina Ruggeri,et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.
[3] A. Órfão,et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.
[4] J. Esteve,et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma , 2005, British journal of haematology.
[5] E. Giné,et al. Smoldering multiple myeloma: natural history and recognition of an evolving type , 2003, British journal of haematology.
[6] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[7] C. Klersy,et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Morgan,et al. Minimal residual disease monitoring in multiple myeloma. , 2002, Best practice & research. Clinical haematology.
[9] A. Órfão,et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. , 2002, Blood.
[10] Terry M Therneau,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.
[11] Joan,et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. , 1998, The American journal of pathology.
[12] M. Dimopoulos,et al. Prognostic features of asymptomatic multiple myeloma , 1997, British journal of haematology.
[13] H. Asaoku,et al. Phenotypic difference of normal plasma cells from mature myeloma cells. , 1993, Blood.
[14] A. Órfão,et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation , 2008 .
[15] J. F. San Miguel Izquierdo,et al. Immunophenotyping of plasma cells in multiple myeloma. , 2005, Methods in molecular medicine.
[16] S. Rajkumar,et al. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. , 2005, Hematology. American Society of Hematology. Education Program.
[17] Gema Mateo Manzanera,et al. Immunophenotyping of Plasma Cells in Multiple Myeloma , 2005 .